Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic
Fiche du document
1 mars 2022
- handle: 10670/1.d6igpy
- halshs: halshs-03448961
info:eu-repo/semantics/OpenAccess
Sujets proches
New drug development Drugs--Development Development of drugs Medications Medicaments Prescription drugs Medicines (Drugs) Pharmaceuticals Medicine (Drugs) Drug trade Drug industryCiter ce document
Émilien Schultz et al., « Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic », HAL-SHS : sociologie, ID : 10670/1.d6igpy
Métriques
Partage / Export
Résumé
During the COVID-19 pandemic, public debates overtly addressed the promises of new innovative treatments. Many of these debates pitted those who advocated for the development of new treatments by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. Data were collected in January 2021 from a quota sample of the French population aged 18–75 years (N = 1,000) during the second round of the “Health Literacy Survey 2019” (HLS19). We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the Navigational Health Literacy score, OR 3.34 [2.13-5.24]) and among those with a high level of trust in pharmaceutical companies or politicians. A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. Respondents who agreed that new drugs are always more effective than old ones were almost four times more likely to agree that drug development should be driven by the pharmaceutical industry (OR 3.85 [2.76-5.39]). A better understanding of public attitudes towards new treatments is needed to elucidate individual preferences in health care and their consequences on health behavior.